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Network. This paper represents a summary of the
Summary
Background Economic evidence for vitiligo treatments is absent.
Objectives To determine the cost-effectiveness of (i) handheld narrowband ultravi-
olet B (NB-UVB) and (ii) a combination of topical corticosteroid (TCS) and NB-
UVB compared with TCS alone for localized vitiligo.
Methods Cost-effectiveness analysis alongside a pragmatic, three-arm, placebo-con-
trolled randomized controlled trial with 9 months’ treatment. In total 517 adults
and children (aged ≥ 5 years) with active vitiligo affecting < 10% of skin were
recruited from secondary care and the community and were randomized 1: 1: 1
to receive TCS, NB-UVB or both. Cost per successful treatment (measured on the
Vitiligo Noticeability Scale) was estimated. Secondary cost–utility analyses mea-
sured quality-adjusted life-years using the EuroQol 5 Dimensions 5 Levels for
those aged ≥ 11 years and the Child Health Utility 9D for those aged 5
to < 18 years. The trial was registered with number ISRCTN17160087 on 8 Jan-
uary 2015.
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economic results. A full and detailed trial report
will be published within the National Institute for
Health Research journal and copyright retained by
the Crown.
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Results The mean  SD cost per participant was £775  837 for NB-UVB,
£813  111.4 for combination treatment and £600  962 for TCS. In analyses
adjusted for age and target patch location, the incremental difference in cost for
combination treatment compared with TCS was £211 (95% confidence interval
188–235), corresponding to a risk difference of 109% (number needed to
treat = 9). The incremental cost was £1932 per successful treatment. The incre-
mental difference in cost for NB-UVB compared with TCS was £173 (95% confi-
dence interval 151–196), with a risk difference of 52% (number needed to
treat = 19). The incremental cost was £3336 per successful treatment.
Conclusions Combination treatment, compared with TCS alone, has a lower incre-
mental cost per additional successful treatment than NB-UVB only. Combination
treatment would be considered cost-effective if decision makers are willing to
pay £1932 per additional treatment success.
What is already known about this topic?
• Vitiligo is a common skin condition with significant psychological impact.
• Topical corticosteroids (TCS) are standard care for vitiligo. Narrowband ultraviolet
B (NB-UVB) is only available in secondary care as full-body treatment.
• Economic evidence for handheld NB-UVB in combination with TCS is absent.
What does this study add?
• Combination treatment, compared with TCS alone, has the lowest incremental cost
per successful treatment. Whether this is considered cost-effective depends on deci-
sion makers’ judgement on how much they are willing to pay to achieve a success-
ful treatment.
• Generic utility instruments, such as the EuroQol 5 Dimensions 5 Levels, may not
be appropriate for vitiligo studies due to high ceiling effects. Measurement of qual-
ity of life for this condition warrants further research.
• This study provides results that can be compared with those of new emerging viti-
ligo treatments.
A 2018 systematic review showed that the economic evidence
for vitiligo treatment is virtually nonexistent.1 One of two
studies identified in this review estimated the annual direct
cost of treating vitiligo in the USA to be $15 million for the
price year 20042 The other study demonstrated that 325% of
people with vitiligo would be willing to make a one-off pay-
ment of €5000 for a cure (2006 price year),3 allowing an
estimate of the maximum potential for benefit should a ‘cure’
be found. Although these papers indicate the cost to an
affected person and healthcare system, they do not provide
evidence to inform resource allocation decisions. No papers
were identified that undertook full economic evaluations
(those that compare costs and benefits of two or more inter-
ventions)4 of vitiligo treatments alongside clinical trials or as
economic modelling. This paper reports the first full economic
evaluation of treatment for localized, nonsegmental vitiligo,
including the current standard treatment topical corticosteroids
(TCS) and new treatment [home-based narrowband ultraviolet
B (NB-UVB)], alone and in combination with TCS, with the
aim of estimating the cost-effectiveness of these treatments for
the UK National Health Service (NHS). Additional explanations
of the terms used in this paper are provided in Appendix S1
(see Supporting Information).
Materials and methods
This health economic evaluation estimated the within-trial
cost-effectiveness of (i) active handheld NB-UVB compared
with TCS (standard care) and (ii) the combination of active
handheld NB-UVB plus TCS compared with TCS (standard
care). Estimates were made in terms of cost per additional
treatment success (henceforth referred to as treatment success)
at the end of the treatment period (9 months) for the treat-
ment of limited, nonsegmental vitiligo, using individual-level
data collected within the trial. A treatment period of 9 months
was chosen to reflect clinical practice, where clinical experi-
ence and clinical guidelines suggest that treatment should be
initiated for a minimum of 3–4 months, but that treatment
would normally be required for a longer period in order to
achieve a clinically meaningful treatment response.
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A secondary objective was to undertake cost–utility analyses
for those aged ≥ 11 years using the EuroQol 5 Dimensions 5
Levels (EQ-5D-5L) and separately for participants
aged < 18 years using the Child Health Utility 9D (CHU-9D).
Typically, a cost–utility analysis would form the primary anal-
ysis as it enables decision makers to compare the cost-effec-
tiveness of a range of interventions for different conditions on
a common scale. As utility is measured differently in adults
and children, a common cost–utility analysis was not possible,
so a clinical outcome was used. Also, cost–utility instruments
are considered less effective at capturing the psychological
impact on quality of life, which is considered to be more
important than physical impacts in vitiligo. A priori we were
also sceptical that available generic utility instruments would
capture the health-related quality-of-life aspects that people
living with vitiligo experience.
The evaluation was undertaken in line with published
guidelines for the economic evaluation of healthcare inter-
ventions.4–8 A health economics analysis plan was written
and approved before the trial database was locked. A full
trial report will be available through the NIHR journal ser-
ies,9 and the clinical results paper is available in this jour-
nal.10
The trial was conducted in the UK NHS, which provides
publicly funded healthcare that is largely free of charge at the
point of use. Therefore, the analysis was primarily from an
NHS perspective, in keeping with the National Institute for
Health and Care Excellence reference case.8 In a sensitivity
analysis, out-of-pocket costs incurred by participants (or par-
ents or guardians) are presented reflecting a personal perspec-
tive.
Resources use and costs
The primary analysis captured the intervention costs (includ-
ing any side-effect costs) to the NHS and the participant’s
wider use of the NHS (including primary care visits; sec-
ondary care outpatient, inpatient and accident and emergency
visits; and prescriptions) as a result of vitiligo. Participants’
personal out-of-pocket expenses (for example, camouflage or
makeup, suncream and sun care) incurred from vitiligo were
also captured in a separate sensitivity analysis taking a broader
perspective. Participant time burden for home treatment was
not costed, but is reported elsewhere.9,10
Resource use data for the intervention phase were collected
at 3, 6 and 9 months using information recorded by partici-
pants in daily diaries and collated by the researcher at follow-
up visits. Resource use related to the intervention and side-ef-
fects was recorded in clinical reports forms. Further question-
naires collected resource use data at 12, 15, 18 and
21 months for the follow-up phase.
Intervention cost was estimated at the individual level. Par-
ticipants randomized to NB-UVB alone were also given a pla-
cebo ointment while those in the TCS alone group received a
dummy NB-UVB device. The dummy devices and placebo
ointment were not costed.
Narrowband ultraviolet B device
The cost of the handheld device was estimated using the man-
ufacturer’s purchase price divided by an annuity factor (inter-
est rate 35%, 5 years) to give an equivalent annual cost. The
equivalent annual cost was divided by 12 months and multi-
plied by 9 to reflect the 9-month timeframe. The purchase
prices of personal protective equipment (goggles and glasses)
were included at full cost as these are unlikely to be as durable
as the devices. Costs of the quality-assurance process for the
devices were included. Device repair and replacement costs
were not included in the analysis. Faulty devices were replaced
in the study, although in practice some might be repaired.
Time spent by investigators training participants on using the
device was recorded and costed.
Topical corticosteroid
Participants in the TCS intervention group were supplied with
two 90-g tubes of mometasone furoate 01% ointment (Elo-
con 01% Ointment; Merck Sharp & Dohme, Hertford, UK).
TCS costs were sourced from the Prescription Cost Analysis for
201711 and had the National Average Discount Percentage of
737% deducted.12 The professional pharmacist fee of £129
was added, assuming that a single tube would be prescribed
at any one time. Additional ointment requested by participants
was recorded and costed.
Trial participants in all treatment groups were offered
appointments with a dermatologist at 0, 3, 6 and 9 months,
as we assumed in the analysis that this would happen in rou-
tine care. These were costed even though they cancel each
other out between treatment groups. Side-effects requiring
medical attention from either treatment were recorded as one
type of unscheduled contact. Unit costs were identified from
published sources (Table 1) and were valued in UK pound
sterling 2017.13,14 Patient-reported estimates of out-of-pocket
costs resulting from vitiligo were captured.
Clinical outcome: treatment success
The primary clinical outcome measure in the HI-Light trial
was participant-reported treatment success, measured at
9 months, using the Vitiligo Noticeability Scale.15 Treatment
success, a binary outcome, was defined by whether the partic-
ipant responded that their target vitiligo patch was ‘a lot less
noticeable’ or ‘no longer noticeable’ in response to the ques-
tion: ‘Compared with the start of the study, how noticeable is
the vitiligo now?’. Because no previous studies have compared
the treatments or outcome used in this study, we used a single
study-based estimate of effectiveness in the cost-effectiveness
analysis.
Quality of life
Quality-adjusted life-years (QALYs) were estimated in sec-
ondary analyses using utility scores obtained from the CHU-
© 2020 The Authors. British Journal of Dermatology
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9D in the analysis focused on children aged < 18 years,16–18
and the EQ-5D-5L instrument for participants
aged ≥ 11 years,19 For participants aged 5–6 years, the
CHU-9D was completed by parental proxy. For all other
ages these instruments were self-completed. We chose to use
just one version of the EQ-5D-5L in the study for consis-
tency. We chose the CHU-9D for the youngest participants
because the EQ-5D-Y (youth) does not currently have a UK
valuation set.
Utility measurements were collected in clinic at baseline
and 9 and 21 months to reflect the likely timeframe for
observing a clinically meaningful treatment response and in
order to observe whether any response found was sustained in
the longer term. In the cost–utility analysis, quality-of-life
instrument responses were converted to utility scores using
the EQ-5D-5L crosswalk20 UK preference weights in line with
current recommendations.21,22 The CHU-9D was valued using
the UK value set.16 Following this, the utility values were used
to calculate QALYs generated over the trial treatment period of
9 months, using both linear interpolation and area-under-the-
curve analysis with baseline adjustment.23
Economic analysis
The economic primary analysis was performed on the full
analysis set. In line with the primary statistical analysis,10 mul-
tiple imputation was used to account for missing primary out-
come data at 9 months. Cost analyses employed multiple
imputation with chained equations using MI impute in Stata
(StataCorp, College Station, TX, USA), generating 60 (m = 60)
datasets using predictive mean matching and separately by
treatment allocation as reported by Faria et al.24 Given the 9-
month time horizon, costs and benefits were not discounted.
Mean  SD resource use and cost per participant were esti-
mated for each randomized group. The mean difference with
95% confidence interval (CI) in resource use and cost between
arms (NB-UVB vs. TCS and combination treatment vs. with
TCS) is presented. Costs and QALYs were adjusted for age and
location of target patch, as well as baseline utility, using seem-
ingly unrelated regression.25
Nonparametric bootstrapping was used to determine sam-
pling uncertainty surrounding the mean incremental cost-ef-
fectiveness ratios by generating
Table 1 Unit costs (UK £ sterling, 2017)
Resource item Unit cost Source (notes)
Intervention resources
Annuity factor 4515 based on
r = 35% and n = 5
Drummond et al.4
Purchase price 14900 Dermfix Ltd website
Annuitized 9-month purchase pricea 2475 Purchase price divided by annuity factor to
give equivalent annual cost (EAC). EAC
divided by 12 months and multiplied by 9
Annuitized 9-month quality assurance
(£1783 multiplied by annuity factor)
296 Quality assurance: Medical Physics,
Nottingham University Hospitals
Glasses (per set) 1500 Dermfix Ltd website
Goggles (per set) 700 Dermfix Ltd website
TCS (per 90-g tube of mometasone furoate 01%) 1213 Health and Social Care Information Centre
prescription cost analysis11
Investigator face-to-face and telephone support
(per minute; assumed band 7, £54 per hour)
090 PSSRU 201713
Dermatologist face-to-face first appointment consultant led 15900 NHS Schedule of Reference Costs14
Dermatologist face-to-face follow-up appointment consultant led 12900 NHS Schedule of Reference Costs14
Dermatologist telephone appointment consultant led 10000 NHS Schedule of Reference Costs14
Training time (per minute; assumed band 7, £54 per hour) 090 PSSRU 201713
Primary care resources (per visit)
General practitioner 3700 PSSRU 201713
Practice nurse 1085 PSSRU 201713
Pharmacist (assumed to be a community pharmacist) 1111 PSSRU 201713
Hospital doctor 5333 PSSRU 201713
Hospital nurse 1500 PSSRU 201713
Therapist 2700 PSSRU 201713
Other (reported by participants) Range from
1500 to 8600
PSSRU 201713 and NHS Schedule of
Reference Costs14
Other resources
Medication (various, NIC per item less NADP plus professional fee) Range from
337 to 3692
PCA 201711
Participant and family out-of-pocket costs Various Estimates reported by participants
NADP, National Average Discount Percentage; NIC, net ingredient cost; PSSRU, Personal Social Services Research Unit; TCS, topical corticosteroids.
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10 000 estimates of incremental costs and benefits. These
estimates were used to produce cost-effectiveness acceptability
curves to show the probability that each intervention arm is
cost-effective at different values of willingness to pay.
Other than preplanned secondary analysis based on the dif-
ferent utility instruments used (EQ-5D-5L and CHU-9D), no
subgroup analyses were undertaken. The secondary outcome
for the economic evaluation was QALYs per participant over
9 months. The mean  SD utility and mean  SD QALYs per
participant per randomized group were estimated, as was the
mean difference (95% CI) in QALYs between arms (NB-UVB
vs. TCS, and combination treatment vs. TCS) adjusted for age
and location of target patch. In secondary analyses, the
reported economic analysis used a cost-effectiveness threshold
of £20 000 per QALY.8 All analyses were conducted in Stata
MP4 version 15.
Sensitivity analyses were undertaken to explore key uncer-
tainties including (i) comparing multiple-imputation analysis
to a complete-case analysis, (ii) varying NB-UVB device costs
(zero and double the price in the primary analysis), (iii) a
wider cost perspective including vitiligo out-of-pocket costs,
(iv) limiting analysis to participants with good adherence (de-
fined as > 75% adherence), and (v) extending the time hori-
zon to 21 months to include the 12-month follow-up period.
It was expected that the majority of costs and benefits
would be captured in the treatment period such that a priori
it was not considered necessary to develop a decision-analyti-
cal model for a longer timeframe. This proved appropriate, as
quality-of-life scores were similar between treatment arms at
21 months.10
Data sharing
Anonymized patient-level data are available from Dr Jonathan
Batchelor (jonathan.batchelor@nottingham.ac.uk) upon rea-
sonable request.
Results
The baseline characteristics of the participants included in the
cost-effectiveness analysis are described in Thomas et al.10
With imputation, 517 participants were included (398 adults,
119 children; 173 TCS, 169 NB-UVB and 175 combined treat-
ment).
Intervention costs
The mean drug and training costs and numbers of devices,
goggles, glasses, dermatology appointments and unscheduled
visits or telephone appointments by group are reported in
Table 2 and the mean costs in Table 3. The mean cost of the
intervention per participant was £583  296 for TCS (stan-
dard care), £753  592 for NB-UVB and £792  946 for
combination treatment. Details of the time and cost of quality-
assurance processes are shown in Table S1 (see Supporting
Information).
The training time was a mean of 731 min for NB-UVB and
692 min for combination treatment, noting that all partici-
pants received both a device and ointment (dummy devices
and placebo ointment were not costed).
Wider resource use and costs
Wider healthcare resource use (primary care, secondary care
and medicines) for vitiligo beyond those required for the
intervention were not significantly different between groups
(Table 2). Patients with vitiligo reported low NHS healthcare
usage. Table 3 displays the mean costs per participant by treat-
ment group using available case data. The overall mean cost
per participant for NB-UVB was £775  837, compared with
£600  962 TCS – an unadjusted mean difference in cost of
£175 (95% CI 153–197). Combination treatment had overall
mean costs per participant of £813  111; compared with
TCS this gave an unadjusted mean difference of £213 (95% CI
188–238) per participant. These figures suggest that the costs
of the interventions were not offset by reductions in wider
healthcare resource use related to vitiligo.
Primary economic analysis
Cost-effectiveness analysis of narrowband ultraviolet B
compared with topical corticosteroid (standard care)
The adjusted incremental difference in cost was £173 (95% CI
151–196). The adjusted risk difference for NB-UVB compared
with TCS was 52%. This equates to a number needed to treat
of 19; in other words, 19 participants would need to be trea-
ted for one of them to gain treatment success. The adjusted
incremental cost was £3336 per additional successful treat-
ment, which was estimated by dividing the adjusted incre-
mental difference in cost, £173, by the adjusted risk
difference, 0052.
Figure 1(a) shows the probability that NB-UVB is cost-effec-
tive at different possible levels of willingness to pay for an addi-
tional treatment success; probability increases as willingness to
pay increases. Figure 1(a) shows considerable uncertainty sur-
rounding the decision as to whether NB-UVB, compared with
TCS, represents value for money, as there is always at least 40%
probability of making the wrong decision if choosing to fund
NB-UVB alone below a threshold value of willingness to pay of
£10 000 per additional treatment success.
Cost-effectiveness analysis of combination treatment
compared with topical corticosteroid (standard care)
The adjusted incremental difference in cost was £211 (95% CI
188–235). The adjusted risk difference for combination treat-
ment compared with TCS was 109%. This equates to a num-
ber needed to treat of 9. The adjusted incremental cost was
£1932 per additional successful treatment.
Figure 1(b) shows the probability that combination treat-
ment is cost-effective at different possible levels of willingness
© 2020 The Authors. British Journal of Dermatology
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to pay for an additional treatment success. It shows that com-
bination treatment is likely to be cost-effective if decision
makers are willing to pay more than £3000 per additional
treatment success, as the probability of making the wrong
decision is < 50%.
Sensitivity analyses exploring key uncertainties in the economic
evaluation are summarized in Table S2 (see Supporting Informa-
tion). Limiting analysis to only adherent participants made the
most difference to the incremental cost-effectiveness ratio (£1151
for combination treatment compared with TCS, and £1394 for
NB-UVB compared with TCS). Those who were adherent to treat-
ment were more likely to be cost-effective to treat.
Secondary economic analysis
In total 248 (55%) trial participants reported having no prob-
lems on any of the five domains of the EQ-5D-5L at baseline,
suggesting that over half of the sample started the study in
perfect health as defined by EQ-5D-5L. To put this value into
perspective, in a general population sample from England the
number of participants reporting no limitations on any dimen-
sion of the EQ-5D-5L was 439%.26 Thus, the ceiling effect in
this study can be considered large and of an order such as to
limit the discriminatory power of the instrument for this
patient population. Similar levels of ceiling effect were
observed at subsequent follow-up. Similarly, for the CHU-9D,
30% of participants aged < 18 years had no problems accord-
ing to any of the nine dimensions on the CHU-9D at baseline.
Anxiety and depression on the EQ-5D-5L, and worry, tired-
ness and sleeping on the CHU-9D were the domains for
which problems were reported most commonly. No floor
effect was observed at any timepoint on either instrument.
As these high ceiling ratios suggest that these instruments
are unlikely to be able to detect change, we report the
Table 2 Mean resource use according to intervention arm over the 9-month treatment phase for all participants (based on available data)
TCS (standard care)
(n = 173), mean
 SD (n)
NB-UVB (n = 169),







mean  SD (n)
Difference
(combination minus




000  000 (173) 108  030 (169) 108 (104 to 113) 107  030 (175) 107 (103 to 112)
Glassesb 000  000 (173) 141  058 (169) 141 (133 to 150) 150  056 (175) 150 (141 to 158)
Gogglesb 000  000 (173) 046  060 (169) 046 (037 to 054) 040  056 (175) 040 (032 to 048)
TCS 215  055 (173) 000  000 (169) 215 (223 to  207) 212  049 (175) 003 (014 to 008)
Training time
(min)




400  000 (173) 400  000 (169) 000 (000 to 000) 400  000 (175) 400 (400 to 400)
Nurse time
(clinic + telephone)
000  000 (173) 200  000 (169) 200 (200 to 200) 200  000 (175) 200 (200 to 200)
Unscheduled clinic
with nurse












002  017 (173) 003  020 (169) 001 (003 to 005) 005  027 (175) 003 (001 to 008)
Primary care
and community
Number 012  044 (136) 017  064 (132) 006 (007 to 019) 012  055 (142) 0002 (012 to 012)
Secondary care
Number 048  447 (136) 020  061 (132) 028 (105 to 049) 020  063 (142) 028 (103 to 046)
Other
Medication 012  050 (138) 008  035 (133) 004 (014 to 006) 009  034 (141) 003 (013 to 007)
Out-of-pocket
purchases
040  144 (141) 028  088 (137) 012 (040 to 016) 031  127 (144) 009 (041 to 023)
CI, confidence interval; NB-UVB, narrowband ultraviolet B; TCS, topical corticosteroid. aIncludes the number of NB-UVB devices only. bPar-
ticipants could choose to have more than one set, for instance if they needed a parent or partner to help them deliver the treatment.
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mean utility estimates in Tables S3 and S4 and the cost–
utility analyses in Table S5 (see Supporting Information).
With this limitation in mind, both NB-UVB and combina-
tion treatment compared with TCS (standard care) had
cost–utility ratios within accepted thresholds (< £20 000
per QALY) for the sample aged ≥ 11 years (NB-UVB was
more superior to TCS than combination treatment was vs.
TCS, in contrast to the cost-effectiveness analysis). Neither
treatment was cost-effective in the analyses of those partici-
pants aged < 18 years, but this may reflect the small sample
size (n = 119).
Discussion
We present the first full economic evaluation of treatments for
vitiligo using the standard care TCS as the comparator. The
additional cost of the combination treatment was not offset by
NHS cost savings but did result in significant treatment success
over the 9-month treatment period. This benefit could be
gained if decision makers were willing to pay more than the
adjusted incremental cost of £1932 per additional successful
treatment. NB-UVB was less costly than combination treatment
but also less effective, such that the incremental cost per
Table 3 Mean costs and outcomes according to intervention arm over the 9-month treatment phase (UK £ Sterling, 2017) for all participants
(based on available data)
TCS (standard
care) (n = 173),
mean  SD (n)
NB-UVB
(n = 169),

















000  000 (173) 296  000 (169) 296 (296 to 296) 296  000 (175) 296 (296 to 296)
Glasses 000  000 (173) 212  874 (169) 212 (199 to 225) 225  834 (175) 225 (212 to 237)
Goggles 000  000 (173) 319  418 (169) 319 (256 to 381) 280  390 (175) 280 (222 to 338)
TCS 261  667 (173) 000  000 (169) 261 (271 to  251) 257  599 (175) 037 (170 to 097)
Training time 000  000 (173) 658  364 (169) 658 (603 to 712) 623  31 (175) 623 (576 to 669)
Dermatologist
(clinic + telephone)
546  000 (173) 546  000 (169) 000 (000 to 000) 546  000 (175) 546 (546 to 546)
Nurse
(clinic + telephone)
000  000 (173) 720  000 (169) 720 (720 to 720) 720  000 (175) 720 (720 to 720)
Unscheduled clinic
with nurse
021  193 (173) 053  364 (169) 032 (029 to 094) 241  953 (175) 220 (075 to 366)
Unscheduled
telephone with nurse








173  1696 (173) 296  202 (169) 122 (274 to 519) 514  268 (175) 341 (133 to 815)
Total cost of
intervention
583  296 (173) 753  592 (169) 170 (1597 to 180) 792  946 (175) 209 (194 to 223)
Primary care and
community
Cost 390  152 (136) 590  222 (132) 200 (256 to 657) 284  141 (142) 106 (452 to 240)
Secondary care
Cost 111  771 (136) 930  301 (132) 174 (159 to 124) 852  269 (142) 253 (161 to 110)
Other
Medication 248  105 (138) 149  706 (133) 099 (314 to 116) 120  609 (140) 128 (330 to 075)
Total mean cost
per participant
600  962 (132) 775  837 (131) 175 (153 to 197) 813  111 (136) 213 (188 to 238)
Out-of-pocket costs 144  968 (141) 494  201 (137) 949 (261 to 712) 662  285 (144) 781 (244 to 875)
Primary outcome
VNS, n/N (%)a 20/119 (168) 27/123 (220) 7 (51)b 34/128 (266) 14 (98)b
aThe number of participants who reported treatment success (on the Vitiligo Noticeability Scale: a lot less noticeable or no longer noticeable)
at 9 months divided by the number of participants with primary outcome recorded at 9 months. bBetween-group difference is the number
of participants experiencing a treatment success (between-group risk difference percentage).
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successful treatment was higher than for combination treat-
ment, suggesting that the NHS would get better value for
money from combination treatment than NB-UVB therapy
alone. There is currently no evidence to indicate how much a
decision maker would be willing to pay for an additional
treatment success as defined in this study. Should the decision
makers’ willingness to pay per additional treatment success be
low, then uncertainty surrounding the decision to fund com-
bination treatment is high. Treatment options are limited for
vitiligo and existing treatments are used little in the NHS,
which may be due to treatments not being offered rather than
absence of need.27
Cost-effectiveness analysis was undertaken as the primary
analysis because it enabled us to analyse all participants
together, irrespective of age. We had a prior belief that gen-
eric utility instruments may not fully capture the health-re-
lated quality-of-life impairment of people living with vitiligo.
This was supported by high ceiling effects on the EQ-5D-5L
and CHU-9D at baseline, such that there was no capacity to
measure any gain using these instruments for many partici-
pants. The cost–utility analysis gave different results from the
clinical and cost-effectiveness results, in that NB-UVB appeared
more cost-effective than combination treatment, compared
with TCS, for those aged ≥ 11 years.
There was also a difference in results between the cost–util-
ity analyses undertaken by age; the new interventions were
estimated as cost-effective in those aged ≥ 11 years but not in
those aged < 18 years. This could reflect the different utility
instrument used, but more likely reflects the small sample size
of the group aged < 18 years and the fact that there was a lot
of uncertainty around the QALYs gained, as the gain between
groups was very close to zero in all comparisons. Therefore,
more weight should be attached to the clinical effectiveness
results and further work to explore the validity of the EQ-5D-
5L and CHU-9D in this patient group is warranted, given the
high ceiling effect observed in this study. It may be that a dis-
ease-specific utility instrument needs to be developed for viti-
ligo.
Sensitivity analyses suggested that a wider perspective, the
cost of the NB-UVB device, and a method of dealing with
missing data did not change the conclusions reached. Incre-
mental cost per treatment success was lowest for those with
greatest adherence.
New treatments such as Janus kinase inhibitors are being
developed for vitiligo and are likely to be costly. The relatively
low cost of the interventions assessed in this trial may make
them affordable when resources are limited. The trial has
yielded useful cost-effectiveness data, which can be used for
future comparisons with novel treatments.
A strength of the study was that the HI-Light trial was a
large, pragmatic trial of home interventions for people with
active, limited vitiligo that controlled for common causes of
bias. Retention throughout the trial was challenging, and the
treatments placed considerable time burden on participants.
Because < 50% responded to secondary outcomes at
21 months, a longer-term economic evaluation to 21 months
was not undertaken, which is a limitation of the present
study. However, given that treatment effects beyond the 9-
month period were not sustained one can assume that the
cost-effectiveness of the interventions would likely decline
over time if treatments were not continued.
In conclusion, combination treatment compared with TCS
alone has a lower incremental cost per successful treatment than
NB-UVB vs. TCS, but whether this is considered cost-effective
will depend on how much healthcare decision makers are willing
to pay to achieve a successful treatment. The fact that vitiligo has
few treatment options available, and the likely high cost of newer
treatments being developed, may influence these decisions.
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